Guidance

Guidance on pharmacovigilance procedures in the event of a no-deal Brexit

This guidance summarises our approach to pharmacovigilance in the event of no-deal Brexit.

This publication was withdrawn on

For current information on pharmacovigilance procedures see European Medicines Agency: Post-authorisation

Updates to this page

Published 18 March 2019
Last updated 9 October 2019 + show all updates
  1. Major changes to content, including two new sections (9 and 10).

  2. Change of text within Stay up to date box.

  3. First published.

Sign up for emails or print this page